Baxter International Announces New Data Showing HDx Therapy With Theranova Dialyzer Reduces All-Cause Mortality Risk By 25% In Four-Year Study Involving 1,000 Dialysis Patients
Portfolio Pulse from Benzinga Newsdesk
Baxter International has announced new data from a four-year study involving 1,000 dialysis patients, showing that its HDx therapy with the Theranova dialyzer reduces all-cause mortality risk by 25%.
May 29, 2024 | 12:46 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Baxter International's HDx therapy with the Theranova dialyzer has shown a 25% reduction in all-cause mortality risk in a four-year study involving 1,000 dialysis patients.
The significant reduction in all-cause mortality risk demonstrated by Baxter's HDx therapy with the Theranova dialyzer is likely to positively impact the company's stock price. This breakthrough could lead to increased adoption of the therapy, boosting revenues and investor confidence.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100